CFD'er er komplekse instrumenter, og der er stor risiko for at miste penge hurtigt på grund af gearing. 84% af individuelle investorer taber penge, når de handler CFD'er med denne udbyder. Du bør overveje, om du forstår, hvordan CFD'er virker, og om du har råd til at løbe en høj risiko for at miste dine penge.

Scan to Download iOS&Android APP

Handel Paratek Pharma - PRTK CFD

2.03
3.33%
  • Opsummering
  • Historisk Data
  • Begivenheder
  • Resultatopgørelse
  • Saldo
  • Cash flow
  • Ejerskab
Handelsbetingelser
Spænd 0.06
Long position, gebyr natten over

Long position overnight fee


Margin. Your investment $1,000.00
Gebyr for natten over -0.030779 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Gå til platform
-0.030779%
Short position, gebyr natten over

Short position overnight fee


Margin. Your investment $1,000.00
Gebyr for natten over -0.013666 %
Charges from borrowed part ($-0.55)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Gå til platform
-0.013666%
Gebyr natten over, tid 22:00 (UTC)
Min. handlet mængde 1
Valuta USD
Margen 20%
Aktiebørs United States of America
Kommission på handel 0%

*Information provided by Capital.com

Nøglestatistikker
Tidligere luk* 2.1
Åben* 2.08
1-Års Ændring* -48.89%
Dagens Spænd* 2.03 - 2.11
52-Ugers Spænd 1.60-4.25
Gennemsnitlig Volumen (10 dage) 228.13K
Gennemsnitlig Volumen (3 måneder) 7.13M
Market Cap 117.77M
P/E-forhold -100.00K
Udestående aktier 55.55M
Omsætning 116.51M
EPS -1.69
Dividend (Udbytte %) N/A
Beta 1.49
Næste indtjeningsopgørelse Mar 13, 2023

Al data kommer fra Refinitiv, med undtagelse af data markeret med en asterisk, som er *data fra Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Luk Change Change (%) Åben High Low
Feb 8, 2023 2.03 -0.05 -2.40% 2.08 2.11 2.03
Feb 7, 2023 2.10 -0.04 -1.87% 2.14 2.15 2.07
Feb 6, 2023 2.11 -0.07 -3.21% 2.18 2.24 2.09
Feb 3, 2023 2.20 0.02 0.92% 2.18 2.28 2.18
Feb 2, 2023 2.24 0.16 7.69% 2.08 2.25 2.08
Feb 1, 2023 2.11 0.00 0.00% 2.11 2.16 2.06
Jan 31, 2023 2.15 0.14 6.97% 2.01 2.15 2.01
Jan 30, 2023 2.03 0.04 2.01% 1.99 2.10 1.98
Jan 27, 2023 2.05 0.00 0.00% 2.05 2.11 2.04
Jan 26, 2023 2.08 0.09 4.52% 1.99 2.08 1.96
Jan 25, 2023 2.03 -0.03 -1.46% 2.06 2.06 1.87
Jan 24, 2023 2.05 -0.09 -4.21% 2.14 2.18 2.05
Jan 23, 2023 2.15 0.05 2.38% 2.10 2.21 2.09
Jan 20, 2023 2.09 0.06 2.96% 2.03 2.10 1.97
Jan 19, 2023 2.01 -0.07 -3.37% 2.08 2.14 2.01
Jan 18, 2023 2.10 -0.30 -12.50% 2.40 2.40 2.06
Jan 17, 2023 2.30 -0.06 -2.54% 2.36 2.38 2.29
Jan 13, 2023 2.37 0.05 2.16% 2.32 2.46 2.30
Jan 12, 2023 2.39 0.14 6.22% 2.25 2.40 2.23
Jan 11, 2023 2.27 -0.01 -0.44% 2.28 2.28 2.21

Paratek Pharma Events

Time (UTC) Country Event
No events scheduled
View all events
  • Årlig
  • Pr kvartal
2016 2017 2018 2019 2020 2021
Total omsætning 0.029 12.616 17.117 16.544 46.924 130.162
Omsætning 0.029 12.616 17.117 16.544 46.924 130.162
Totale Driftsudgifter 109.515 97.196 121.202 132.173 124.796 171.292
Salgs/Generelle/Admin. Udgifter, Total 26.4 36.965 63.658 89.135 89.355 119.004
Forskning & Udvikling 83.46 60.072 57.508 39.554 23.922 30.353
Renteudgift (Indkomst) - Netto Drift -0.345 -0.584 -0.071 0
Usædvanlig Udgift (Indkomst) 0 0.743 0.107 0 2.368 0
Driftsindtægter -109.486 -84.58 -104.085 -115.629 -77.872 -41.13
Renteindkomst (Udgift), Netto Ikke-Drift -2.154 -3.702 -7.725 -12.829 -18.725 -17.342
Andre, Netto 0.004 -0.034 -0.044 -0.031 0.056 -0.012
Netto Indkomst Før Skat -111.636 -88.316 -111.854 -128.489 -96.541 -58.484
Netto Indkomst Efter Skat -111.636 -89.069 -112.356 -128.79 -96.541 -59.084
Netto Indkomst Før Ekstra Ting -111.636 -89.069 -112.356 -128.79 -96.541 -59.084
Netto Indkomst -111.636 -89.069 -112.356 -128.79 -96.541 -59.084
Total Adjustments to Net Income 0
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting -111.636 -89.069 -112.356 -128.79 -96.541 -59.084
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting -111.636 -89.069 -112.356 -128.79 -96.541 -59.084
Fortyndet Netto Indkomst -111.636 -89.069 -112.356 -128.79 -96.541 -59.084
Fortyndet Vægtet Gennemsnit Aktier 20.2531 26.8272 31.5135 32.7919 44.1748 48.4155
Fortyndet EPS Uden Ekstraordinære Ting -5.51205 -3.32009 -3.56533 -3.92749 -2.18543 -1.22035
Fortyndet Normaliseret EPS -5.51205 -3.30209 -3.56313 -3.92749 -2.13183 -1.22035
Kost af omsætning, Total 3.484 8.651 21.535
Bruttofortjeneste 13.06 38.273 108.627
Depreciation / Amortization 0.5 0.4
Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022
Total omsætning 16.427 57.492 24.447 31.797 24.861
Omsætning 16.427 57.492 24.447 31.797 24.861
Kost af omsætning, Total 2.751 9.778 4.289 4.718 3.494
Bruttofortjeneste 13.676 47.714 20.158 27.079 21.367
Totale Driftsudgifter 30.648 43.403 38.164 59.078 38.574
Salgs/Generelle/Admin. Udgifter, Total 22.359 27.106 25.955 43.984 27.602
Forskning & Udvikling 5.538 6.519 7.92 10.376 7.478
Driftsindtægter -14.221 14.089 -13.717 -27.281 -13.713
Renteindkomst (Udgift), Netto Ikke-Drift -4.282 -4.333 -4.342 -4.384 -4.372
Andre, Netto 0.157 -0.039 -0.143 0.012 0.175
Netto Indkomst Før Skat -18.346 9.717 -18.202 -31.653 -17.91
Netto Indkomst Efter Skat -18.346 9.717 -18.202 -32.253 -17.91
Netto Indkomst Før Ekstra Ting -18.346 9.717 -18.202 -32.253 -17.91
Netto Indkomst -18.346 9.717 -18.202 -32.253 -17.91
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting -18.346 9.717 -18.202 -32.253 -17.91
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting -18.346 9.717 -18.202 -32.253 -17.91
Fortyndet Netto Indkomst -18.346 9.717 -18.202 -32.253 -17.91
Fortyndet Vægtet Gennemsnit Aktier 46.6644 48.9457 49.214 50.6329 52.1495
Fortyndet EPS Uden Ekstraordinære Ting -0.39315 0.19853 -0.36985 -0.637 -0.34344
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Fortyndet Normaliseret EPS -0.39315 0.19853 -0.36985 -0.637 -0.34344
Usædvanlig Udgift (Indkomst) 0
  • Årlig
  • Pr kvartal
2016 2017 2018 2019 2020 2021
Totale Nuværende Aktiver 132.1 160.486 255.243 243.354 164.117 152.1
Likvider og Kortsigtede Investeringer 128.038 151.723 250.351 215.379 125.162 95.474
Likvider & Lignende 52.962 35.416 46.987 102.302 105.157 80.367
Kortsigtede Investeringer 75.076 116.307 203.364 113.077 20.005 15.107
Totale Tilgodehavender, Netto 0.323 5.889 0.249 9.583 15.733 33.117
Accounts Receivable - Trade, Net 0.323 5.889 0.249 9.583 15.733 33.117
Prepaid Expenses 2.922 2.712 4.377 6.489 7.776 12.364
Other Current Assets, Total 0.817 0.162 0.266 0.324 0.891 0.125
Total Assets 135.732 163.698 300.192 251.079 176.853 183.869
Property/Plant/Equipment, Total - Net 1.188 1.711 1.173 3.741 2.974 2.551
Property/Plant/Equipment, Total - Gross 2.009 2.925 2.985 6.077 5.761 4.814
Accumulated Depreciation, Total -0.821 -1.214 -1.812 -2.336 -2.787 -2.263
Goodwill, Net 0.829 0.829 0.829 0.829 0.829 0.829
Intangibles, Net 1.015 0.142 0
Other Long Term Assets, Total 0.6 0.53 0.46 3.155 8.933 28.389
Total Current Liabilities 20.412 16.789 17.709 24.2 23.953 31.297
Accounts Payable 4.467 3.679 2.09 4.116 1.813 5.394
Accrued Expenses 15.889 13.11 15.619 17.696 21.626 24.046
Notes Payable/Short Term Debt 0 0 0 0 0 0
Other Current Liabilities, Total 0.056 2.388 0.514 1.857
Total Liabilities 64.14 81.22 252.614 290.726 279.113 311.656
Total Long Term Debt 39.629 59.257 228.959 260.728 250.474 254.428
Long Term Debt 39.629 59.257 228.959 260.728 250.474 254.428
Other Liabilities, Total 4.099 5.174 5.946 5.798 4.686 25.931
Total Equity 71.592 82.478 47.578 -39.647 -102.26 -127.787
Preferred Stock - Non Redeemable, Net 0 0 0
Common Stock 0.023 0.028 0.032 0.04 0.046 0.052
Additional Paid-In Capital 451.947 552.72 630.142 671.497 705.489 739.053
Retained Earnings (Accumulated Deficit) -380.362 -470.112 -582.468 -711.258 -807.799 -866.883
Other Equity, Total -0.016 -0.158 -0.128 0.074 0.004 -0.009
Total Liabilities & Shareholders’ Equity 135.732 163.698 300.192 251.079 176.853 183.869
Total Common Shares Outstanding 23.3586 27.941 32.2594 39.8278 46.5166 51.7118
Long Term Investments 42.487 0
Total Inventory 11.579 14.555 11.02
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Totale Nuværende Aktiver 141.831 153.504 153.011 152.1 133.282
Likvider og Kortsigtede Investeringer 103.45 75.298 110.999 95.474 79.053
Likvider & Lignende 103.45 75.298 110.999 80.367 49.033
Kortsigtede Investeringer 0 0 0 15.107 30.02
Totale Tilgodehavender, Netto 18.538 60.809 22.132 33.117 28.259
Accounts Receivable - Trade, Net 18.538 60.809 22.132 33.117 28.259
Total Inventory 14.207 7.954 8.824 11.02 12.732
Prepaid Expenses 5.212 9.318 10.931 12.364 12.988
Other Current Assets, Total 0.424 0.125 0.125 0.125 0.25
Total Assets 159.277 179.588 182.348 183.869 170.157
Property/Plant/Equipment, Total - Net 2.744 3.07 2.688 2.551 2.298
Goodwill, Net 0.829 0.829 0.829 0.829 0.829
Other Long Term Assets, Total 13.873 22.185 25.82 28.389 33.748
Total Current Liabilities 22.957 20.977 29.15 31.297 28.837
Accounts Payable 4.045 2.59 4.991 5.394 4.697
Accrued Expenses 18.33 18.061 23.764 24.046 22.733
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0.582 0.326 0.395 1.857 1.407
Total Liabilities 278.285 278.879 287.341 311.656 310.459
Total Long Term Debt 250.809 252.759 253.269 254.428 255.949
Long Term Debt 250.809 252.759 253.269 254.428 255.949
Other Liabilities, Total 4.519 5.143 4.922 25.931 25.673
Total Equity -119.008 -99.291 -104.993 -127.787 -140.302
Preferred Stock - Non Redeemable, Net 0 0 0
Common Stock 0.047 0.048 0.05 0.052 0.053
Additional Paid-In Capital 707.09 717.089 729.587 739.053 744.618
Retained Earnings (Accumulated Deficit) -826.145 -816.428 -834.63 -866.883 -884.793
Other Equity, Total 0 0 0 -0.009 -0.18
Total Liabilities & Shareholders’ Equity 159.277 179.588 182.348 183.869 170.157
Total Common Shares Outstanding 46.9072 47.9965 50.0202 51.7118 53.0233
  • Årlig
  • Pr kvartal
2016 2017 2018 2019 2020 2021
Netto indkomst/Startlinje -111.636 -89.069 -112.356 -128.79 -96.541 -59.084
Likvider Fra Driftsaktiviteter -94.098 -78.574 -81.179 -134.045 -103.424 -48.273
Likvider Fra Driftsaktiviteter 2.303 1.268 0.578 0.391
Ikke-Likvide Ting 10.688 17.467 27.254 16.483 12.825 18.609
Likvid Rente Betalt 1.582 3.705 9.31 15.96 22.703 13.144
Ændringer i Driftskapital 4.547 -8.24 3.923 -21.738 -20.286 -8.189
Likvider fra Investeringsaktiviteter -74.757 -42.002 -127.874 134.554 92.499 4.51
Kapitaludgifter -0.69 -1.117 -0.06 -0.239 -0.376 -0.373
Andre Investerings-Cash-Flow-Ting, Total -74.067 -40.885 -127.814 134.793 92.875 4.883
Likvider fra Financieringsaktiviteter 90.515 103.03 220.727 57.622 11.34 18.332
Financiering af Cash-Flow-Ting 0
Udstedelse (Pensionering) af Aktier, Netto 70.941 83.115 51.803 27.068 22.623 19.048
Udstedelse (Pensionering) af Gæld, Netto 19.574 19.915 168.924 30.554 -11.283 -0.716
Netto Ændring i Likviditet -78.34 -17.546 11.674 58.131 0.415 -25.431
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line -18.346 -8.629 -26.831 -59.084 -17.91
Cash From Operating Activities -21.518 -54.724 -28.465 -48.273 -19.11
Cash From Operating Activities 0.11 0.225 0.313 0.391 0.144
Non-Cash Items 1.934 7.274 10.476 18.609 3.99
Cash Interest Paid 0.975 5.865 7.664 13.144 1.181
Changes in Working Capital -5.216 -53.594 -12.423 -8.189 -5.334
Cash From Investing Activities 19.738 19.621 19.627 4.51 -15.196
Capital Expenditures -0.262 -0.379 -0.373 -0.373 -0.036
Other Investing Cash Flow Items, Total 20 20 20 4.883 -15.16
Cash From Financing Activities -0.394 4.603 14.039 18.332 3.097
Issuance (Retirement) of Stock, Net 0.003 5 14.436 19.048 3.097
Issuance (Retirement) of Debt, Net -0.397 -0.397 -0.397 -0.716 0
Net Change in Cash -2.174 -30.5 5.201 -25.431 -31.209
Investornavn Investortype Procent udestående Aktiebeholdning Aktieændring Beholdningsdato IOmsætningsscore
AIGH Capital Management, LLC. Private Equity 6.9977 3887172 0 2022-09-30 MED
Dugaboy Investment Trust Corporation 6.9671 3870197 978000 2022-12-31 LOW
Lytton (Laurence W) Individual Investor 5.7796 3210552 3210552 2022-05-09
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 3.9148 2174625 154939 2022-09-30 LOW
Omega Fund Management, LLC Investment Advisor 3.5486 1971241 0 2022-09-30 LOW
General American Investors Company, Inc. Investment Advisor 3.4494 1916099 163629 2022-09-30 LOW
Medical Strategy GmbH Investment Advisor 3.2706 1816780 0 2022-09-30 LOW
Rock Springs Capital Management LP Hedge Fund 3.1216 1734037 0 2022-09-30 LOW
Bruce & Company, Inc. Investment Advisor 2.8035 1557312 0 2022-09-30 LOW
Loh (Evan) Individual Investor 2.1751 1208238 -70739 2022-12-21 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 2.1097 1171910 334401 2022-09-30 LOW
Abingworth Management Limited Venture Capital 1.8742 1041131 0 2022-09-30 LOW
Worth Venture Partners, LLC Investment Advisor/Hedge Fund 1.7456 969698 0 2022-09-30 MED
Two Sigma Investments, LP Hedge Fund 1.3409 744866 491611 2022-09-30 HIGH
Bigham (Michael F) Individual Investor 1.1934 662937 -22125 2022-12-21 LOW
Woodrow (Adam) Individual Investor 1.1724 651284 5677 2022-12-21 LOW
1492 Capital Management, LLC Investment Advisor/Hedge Fund 0.902 501050 11674 2022-09-30 MED
J. Goldman & Co., L.P. Hedge Fund 0.8263 459000 438647 2022-09-30
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.7956 441935 5616 2022-09-30 LOW
Haskel William M Individual Investor 0.7341 407800 -30001 2022-12-21 LOW

Hvorfor vælge Capital.com? Vores tal taler for sig selv.

Capital.com Group
+500000+

Handlende

93000+

Månedlkige, aktive klienter

$57000000+

Månedlig investeringsvolumen

$31000000+

Hævet hver måned

Handelslommeregner

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Handelskurtage
0
  • 1:1
  • 2:1
  • 5:1
  • 10:1
  • 20:1
Gearing
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investering
Handelsstørrelse (Gearing x Investering):
Åben

Luk

Short Long

Paratek Pharma Company profile

Om Paratek Pharma

Paratek Pharmaceuticals, Inc. er en biofarmaceutisk virksomhed i den kommercielle fase. Selskabet er fokuseret på udvikling og markedsføring af nye livreddende behandlinger mod livstruende sygdomme. Selskabets produkt omfatter NUZYRA (omadacyclin) er et oralt og intravenøst antibiotikum til behandling af bakteriel lungebetændelse og akutte infektioner i hud og hudstruktur forårsaget af modtagelige patogener. Selskabets andre produkter omfatter SEYSARA, som er et oralt behandlingsmiddel til behandling af moderat til svær acne vulgaris.

Industry: Pharmaceuticals (NEC)

75 Park Plaza
4Th Floor
BOSTON
MASSACHUSETTS 02116
US

Resultatopgørelse

  • Annual
  • Quarterly

Folk ser også

Oil - Crude

78.66 Price
-0.140% 1D Chg, %
Long position, gebyr natten over -0.0163%
Short position, gebyr natten over 0.0021%
Gebyr natten over, tid 22:00 (UTC)
Spænd 0.03

BTC/USD

22,733.20 Price
-1.150% 1D Chg, %
Long position, gebyr natten over -0.0500%
Short position, gebyr natten over 0.0140%
Gebyr natten over, tid 22:00 (UTC)
Spænd 60.00

US100

12,630.90 Price
+0.850% 1D Chg, %
Long position, gebyr natten over -0.0191%
Short position, gebyr natten over 0.0077%
Gebyr natten over, tid 22:00 (UTC)
Spænd 1.8

XRP/USD

0.40 Price
-1.250% 1D Chg, %
Long position, gebyr natten over -0.0500%
Short position, gebyr natten over 0.0140%
Gebyr natten over, tid 22:00 (UTC)
Spænd 0.00319

Leder du stadig efter en mægler, du kan stole på?

Deltag sammen med 500.000+ handlende over hele verden, der valgte at handle hos Capital.com

1. Opret og bekræft din konto 2. Lav en inddbetaling 3. Find din handel